Of course. Here is the summary of Alzheimer’s disease drugs presented in a document format.
Summary of Alzheimer’s Disease Drugs for Dental Practice
This summary outlines the key pharmacological agents used for Alzheimer’s disease and their specific implications for dental practice, based on the provided lecture notes.
🧠 Anticholinesterases
Anticholinesterase drugs are used in early-stage Alzheimer’s disease to increase the availability of acetylcholine in the brain by reducing its breakdown.
-
Example Drugs: Donepezil (Arazil, Aricept), Galantamine (Galantyl, Reminyl), and Rivastigmine (Exelon).
-
Adverse Drug Reactions (ADRs): Common side effects relevant to the dental setting include drowsiness, dizziness, tremor, increased sweating, hypertension, and fainting.
-
Dental Management & Considerations:
-
The risk of dizziness and fainting can complicate patient positioning and their ability to tolerate treatment.
-
Drug interactions are a key concern. CYP3A4 inhibitors like erythromycin or fluconazole should be avoided if possible.
-
Specifically with galantamine, caution is required when prescribing medications known to prolong the QT interval, such as clarithromycin, erythromycin, and fluconazole.
-
🧠 NMDA Antagonists
N-methyl-D-aspartate (NMDA) antagonists work by blocking NMDA receptors to prevent neuronal damage caused by excessive glutamate stimulation.
-
Example Drug: Memantine (Ebixa, Memanxa).
-
Adverse Drug Reactions (ADRs): Common side effects include confusion, dizziness, drowsiness, headache, agitation, and hallucinations. Anxiety is an infrequent side effect.
-
Dental Management & Considerations:
-
Side effects like confusion, agitation, and hallucinations can severely complicate communication and patient cooperation during dental procedures.
-
Management strategies include using calm communication, providing clear and simple instructions, scheduling shorter appointments, and involving a familiar caregiver to help reduce the patient’s anxiety.
-
Overall Patient Management
When treating any patient with Alzheimer’s disease, regardless of their specific medication, two factors are critical:
-
Cognitive Assessment: The dentist must recognize and assess the patient’s level of cognitive decline before proceeding with treatment.
-
Informed Consent: It is essential to ensure valid consent is obtained. Depending on the patient’s cognitive state, this may require the involvement of a caregiver or legal power of attorney.